| Ytd | 21.83% | |
| 1y | 158.74% |
| Open | Prev Close | 23.83 | Low | High | Mkt Cap | 3.94B | |||
| Vol | 0.00 | Avg Vol | 1.83M | EPS | -3.22 | P/E | -7.40 | Forward P/E | -8.10 |
| Beta | 1.06 | Short Ratio | 14.55 | Inst. Own | 115.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-27 | 50-d Avg | 19.91 | 200-d Avg | 18.66 | 1yr Est | 38.25 |
DYN News
WALTHAM, Mass. , July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical
Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program
Dyne Therapeutics receives FDA Priority Review for z-rostudirsen in DMD, with a potential U.S. launc
- Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Acce
Dyne Therapeutics is advancing a clinical-stage platform specifically targeting genetically driven n
Dyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its prop
Dyne is advancing therapies for rare muscle diseases while Viking targets the booming weight-loss ma
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-
WALTHAM, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50
- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALT
DYN shares jump after the company files a BLA with the FDA for z-rostudirsen in Duchenne muscular dy
- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registr
Dyne Therapeutics, Inc. retains a Strong Buy rating, driven by clinical progress in DM1 and DMD prog
DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystroph
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-s
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Pr
Dow Jones index up 200 points on Tuesday, NIO Inc. gained following better-than-expected financial r
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh
On Tuesday, 647 companies set new 52-week lows.
On Friday, 209 companies set new 52-week lows.